Many Growth Opportunities Emerging in the U.S. Infectious Disease In-Vitro Diagnostics Market
Posted on: Friday, 16 February 2007, 12:01 CST
Research and Markets (http://www.researchandmarkets.com/reports/c50504) has announced the addition of Frost & Sullivan's new report: U.S. Infectious Disease Diagnostics Markets to their offering.
This research service, titled U.S. Infectious Disease Diagnostics Markets, provides comprehensive analysis of market drivers, restraints, challenges, and trends. Moreover, analysis of market share, competitive structure, revenue forecasts, and products is included. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: molecular infectious disease diagnostics, immunoassay infectious disease diagnostics, and culture infectious disease diagnostics.
Market Sectors
Expert analysts thoroughly examine the following market sectors in this research:
-- Molecular
-- Immunoassay
-- Culture
Technologies
The following technologies are covered in this research:
-- PCR
-- Automated antimicrobial susceptibility testing
-- Molecular technologies and assays
-- Immunoassays
-- Microbiology culture methods
Market Overview
The U.S. infectious disease diagnostics market will play a significant role in the dynamic IVD market. This market is segmented according to molecular, immunoassays, and culture infectious disease products. Total market revenues for base year 2005 are $3,823.1 with a CAGR of 7.7%. The most substantial growth is expected in the molecular segment. The U.S. infectious disease diagnostics market is highly competitive and saturated.
Tremendous growth opportunities exist in the U.S. infectious disease in-vitro diagnostics market. High growth areas include viral load testing, nosocomial infection screening, rapid influenza detection, and STD testing.
Rapid detection and fast turn-around time (TAT) are able to lower total overall healthcare costs. Quick TAT is especially relevant to infectious disease testing, as fast diagnosis increases treatment options and patient prognosis.
Technical superiority of molecular methods is phasing out other types or more traditional methods, such as culture based tests, which have TATs of only days and are labor intensive.
For more information visit http://www.researchandmarkets.com/reports/c50504
Source: Business Wire
Related Articles
- Reportlinker Adds Infectious Disease Diagnostic Markets Report
- The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases
- Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
- Focus Diagnostics Launches Chikungunya Virus Test
- Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
- INOVA Diagnostics, Inc. Lauded for Its Leadership in the U.S. Autoimmune Disease Diagnostic Markets
- Remarks By the First Lady in a Roundtable Discussion at Howard University's Center for Infectious Disease Management and Research
- Big Pharma Has Rediscovered the Anti-Infectives Market and Is Bolstering Its Pipelines Through Licensing Agreements And Acquisitions - More Inside Infectious Diseases Report
- The U.S. Infectious Disease Diagnostics Market Plays Significant Role in the Dynamic IVD Market
 |
 |
User Comments (0)
RSS Feeds